Skip to content

Author

S. Nishat

We have 2 of 23 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Synergistic IL-1 pathway genetic variants amplify susceptibility and inflammatory severity in COVID-19

IL-1 pathway genetic variants are associated with COVID-19 susceptibility and inflammatory biomarker profiles and integration of host genetic markers with clinical factors may improve risk stratification and support precision immunomodulatory strategies.

HariOm Singh, Aishwarya Nair, Goldi Namdev et al. · 0 citations
Jul 2026

Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.

A trispecific CAR targeting CD19, CD20, and CD22 with OX40 co-stimulatory domain with overall response rate was 50%, including complete responses in 83% of lymphoma patients, and one-year overall survival rate was 61%, with durable remissions observed in lymphoma.

S. Vasu, N. Denlinger, No-Joon Song et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.